Transfusion associated graft-versus-host disease, cytomegalovirus infection and HLA alloimmunization in neonatal and pediatric patients (Q33867797)

29 July 2017

1 reference

title

Transfusion associated graft-versus-host disease, cytomegalovirus infection and HLA alloimmunization in neonatal and pediatric patients (English)

1 reference

29 July 2017

0 references

cytomegaloviral disease

1 reference

Hume HA

1

1 reference

PubMed ID

10724787

29 July 2017

Preiksaitis JB

series ordinal

2

1 reference

29 July 2017

1 August 1999

1 reference

29 July 2017

1 reference

29 July 2017

21

1 reference

29 July 2017

1

1 reference

29 July 2017

73-95

1 reference

Graft-versus-host reaction following blood product transfusion

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Survey of transfusion-associated graft-versus-host disease in immunocompetent recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Posttransfusion graft-versus-host disease in Japanese newborns

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Establishment of a T-cell line from lymphocytes presumably implicated in posttransfusion graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Restricted use of T-cell receptor V beta genes in posttransfusion graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Transfusion-associated graft-versus-host disease: new insights and a route towards therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Transfusion-associated graft-versus-host disease caused by leukocyte-filtered stored blood.

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Aplastic anemia, histiocytosis and erythrodermia in immunologically deficient children. Probable human runt disease

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Aplastic anemia and alymphocytosis in an infant with hypogammaglobulinemia: graft-versus-host reaction?

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Human Posttransfusion Graft-versus-Host Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Irradiation of blood products. Indications and guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Erythropoietin for the treatment of porphyria cutanea tarda in a patient on long-term hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Transfusion-associated graft-versus-host disease: historical perspectives, incidence, and current use of irradiated blood products

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Third party mediated graft rejection despite irradiation of blood products

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Use of irradiated blood components: practice parameter

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Potential for transfusion-associated graft-versus-host disease due to apheresis platelets matched for HLA class I antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Brief report: graft-versus-host disease associated with transfusion of blood from unrelated HLA-homozygous donors

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Fatal graft-versus-host disease associated with transfusions of HLA-matched, HLA-homozygous platelets from unrelated donors

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Risk of transfusion-associated graft-versus-host disease as a result of directed donations from relatives

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Transfusion-associated graft-versus-host disease: risk due to homozygous HLA haplotypes.

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Posttransfusion graft-versus-host disease in infancy

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Multiple areas of intestinal atresia associated with immunodeficiency and posttransfusion graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Graft-versus-host disease following ECMO

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

A survey of Canadian neonatal blood transfusion practices

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Transfusion-associated graft-versus-host disease in the neonate-expanding the spectrum of disease

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Are guidelines for use of gamma irradiation for the prevention of transfusion-associated graft-versus-host disease adequate for newborns?

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Moderate and transient transfusion-associated cutaneous graft-versus-host disease in a child infected by human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Transfusion practices in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Principles of blood irradiation, dose validation, and quality control

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

The effects of irradiation on blood components

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

The effect of prestorage irradiation on posttransfusion red cell survival

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Routinely washing irradiated red cells before transfusion seems unwarranted

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

The irradiation of blood and blood components to prevent graft-versus-host disease: technical issues and guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Ultraviolet irradiation modulates MHC-alloreactive cytotoxic T-cell precursors involved in the onset of graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Successful treatment of transfusion-associated graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Potential usefulness of protease inhibitor and chloroquine in the treatment of transfusion-associated graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Potential usefulness of photochemotherapy using 8-methoxypsoralen in the treatment of posttransfusion graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Immunosuppressive effects of chloroquine: potential effectiveness for treatment of post-transfusion graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Transfusion transmission of cytomegalovirus confirmed by restriction endonuclease analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Risk factors for cytomegalovirus infection after human marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

The risk of cytomegalovirus infection in seronegative transfusion recipients not receiving exogenous immunosuppression

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Prevalence of cytomegalovirus antibody in hemophiliacs and homosexuals infected with human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Human cytomegalovirus in blood of immunocompetent persons during primary infection: prognostic implications for pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Latent cytomegalovirus infection in blood donors.

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Relation of Titers of Antibodies to CMV in Blood Donors to the Transmission of Cytomegalovirus Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Prevention of transfusion-associated cytomegalovirus (CMV) infection in neonates by screening blood donors for IgM to CMV

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Failure to Detect Human Cytomegalovirus DNA in IgM-Seropositive Blood Donors by Spot Hybridization

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Transfusion- and community-acquired cytomegalovirus infection in children with malignant disease: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Polymerase chain reaction for detection of human cytomegalovirus infection in a blood donor population

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Cytomegalovirus DNA can be detected in peripheral blood mononuclear cells from all seropositive and most seronegative healthy blood donors over time

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Persistence of cytomegalovirus in mononuclear cells in peripheral blood from blood donors

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

The presence of free infectious cytomegalovirus (CMV) in the plasma of donated CMV-seropositive blood and platelets

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Acquisition of cytomegalovirus infection in infants following exchange transfusion: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Cytomegalovirus and blood transfusion in neonates

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Reduction of postperfusion cytomegalovirus-infections following the use of leukocyte depleted blood

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Posttransfusion cytomegalovirus infection in neonates: role of saline-washed red blood cells

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Low incidence of acquired cytomegalovirus infection in neonates transfused with washed red blood cells

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Use of Deglycerolized Red Blood Cells to Prevent Posttransfusion Infection with Cytomegalovirus in Neonates

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Use of leucocyte-poor blood components to prevent primary cytomegalovirus (CMV) infection in patients with acute leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Prevention of primary cytomegalovirus infection in patients with hematologic malignancies by intensive white cell depletion of blood products

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Factors influencing white cell removal from red cell concentrates by filtration.

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Optimal conditions for white cell reduction in red cells by filtration at the patient's bedside

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

The risk of transmitting cytomegalovirus to patients receiving blood transfusions

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Severe cytomegalovirus infection in multiply transfused, splenectomized, trauma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Acquisition of donor strains of cytomegalovirus by renal-transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Cytomegalovirus infection and reinfection transmitted by heart transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Isolation of multiple strains of cytomegalovirus from women attending a clinic for sexually transmitted disease

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Identification of Multiple Cytomegalovirus Strains in Homosexual Men with Acquired Immunodeficiency Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Use of cytomegalovirus immunoglobulin in multiply transfused premature neonates

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Sequelae of maternally derived cytomegalovirus infections in premature infants

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Development of the immune system in very low birth weight (less than 1500 g) premature infants: concentrations of plasma immunoglobulins and patterns of infections

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Cytomegalovirus infections in seropositive patients after transfusion. The effect of red cell storage and volume

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Cytomegalovirus infection in patients with AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Bidirectional interactions between human immunodeficiency virus type 1 and cytomegalovirus

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components--a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Meta-analysis of randomized controlled trials of the efficacy of white cell reduction in preventing HLA-alloimmunization and refractoriness to random-donor platelet transfusions

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Systematic use of leukocyte-free blood components to prevent alloimmunization and platelet refractoriness in multitransfused children with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

Evidence-based medicine: the case for white cell reduction

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2899%2900067-3

7 January 2021

10.1016/S0955-3886(99)00067-3

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10724787